ASTRAZENECA PICKS UP 2ND ARRAY COMPOUND
Array BioPharma Inc. said Tuesday that AstraZeneca PLC selected another of the
drugs they are developing to enter human trials, triggering a $1 million payment
from AstraZeneca to Array. The two pharmaceutical companies agreed in 2003 to
develop the first compound, a potential cancer therapy called ARRY-142886, and
to collaborate on developing other therapies. That first treatment is currently
in early stage studies.